Human papillomavirus infection

Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

Retrieved on: 
Tuesday, November 1, 2022

FRANKFURT, Germany, Nov. 1, 2022 /PRNewswire/ -- Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling a latent unmet clinical need for patients with the Human Papilloma Virus (HPV). As the largest pharma industry event worldwide, CPHI Frankfurt will allow thousands of participants to have a first look at this innovative product, whose exclusive formula helps to counteract the signs, symptoms, and persistence of HPV.

Key Points: 
  • Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners.
  • Pervistop promises to be an extremely effective tool in the management of an exceedingly unpredictable disease.
  • HPV is the most common sexually transmitted infection worldwide, and it is known to cause certain cancers and genital warts.
  • Pharma International is committed to supporting our Partners through equitable, exclusive distribution agreements, while sharing the scientific know-how and marketing strategies, which are needed to be successful.

HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers

Retrieved on: 
Thursday, October 20, 2022

Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers.

Key Points: 
  • Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers.
  • The agreement also includes an option for Roche to license a second arenaviral cancer immunotherapy.
  • Roche is an ideal partner, both in terms of development and reaching patients with novel cancer therapeutics.
  • HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers.

The Grand Hamdan Award goes to two scientists in Australia

Retrieved on: 
Tuesday, October 18, 2022

Late Dr. Jian Zhou was the Lion Principal Research Fellow, Chair HPV Structure Protein Laboratory at the Centre for Immunology and Cancer Research of the University of Queensland Faculty of Medicine, Brisbane, Australia.

Key Points: 
  • Late Dr. Jian Zhou was the Lion Principal Research Fellow, Chair HPV Structure Protein Laboratory at the Centre for Immunology and Cancer Research of the University of Queensland Faculty of Medicine, Brisbane, Australia.
  • Prof. Ian Frazer says that we could not have achieved this historic breakthrough without the contribution of Dr. Jian Zhou, who sadly passed away in 1999.
  • Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences is a non-profit organization that honors researchers worldwide who carry out distinguished medical research to serve humanity.
  • Also, the Award stimulates scientific interaction and enriches scientific research among doctors in the UAE and overseas.

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Retrieved on: 
Thursday, October 6, 2022

VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L. ("Procare Health"), of Barcelona, Spain ("Procare Health"), for exclusive marketing and distribution in the United States of Procare Health's leading patented product, Papilocare™, the world's first and only vaginal gel product with clinical evidences to prevent and treat HPV-dependent cervical lesions, and for Immunocaps®, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.  As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval is not required, allowing the rapid build out of sales channels and revenue generation from the product.

Key Points: 
  • VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company")announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L.
  • Under the Term Sheet, BioVaxys will have responsibility for US regulatory approval for Papilocareand anticipates US registration as a Class II medical device.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Retrieved on: 
Thursday, October 6, 2022

VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L. ("Procare Health"), of Barcelona, Spain ("Procare Health"), for exclusive marketing and distribution in the United States of Procare Health's leading patented product, Papilocare™, the world's first and only vaginal gel product with clinical evidences to prevent and treat HPV-dependent cervical lesions, and for Immunocaps®, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.  As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval is not required, allowing the rapid build out of sales channels and revenue generation from the product.

Key Points: 
  • VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company")announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L.
  • Under the Term Sheet, BioVaxys will have responsibility for US regulatory approval for Papilocareand anticipates US registration as a Class II medical device.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

Microbix Presenting Test-Workflow Validation Results at EMMD

Retrieved on: 
Thursday, October 6, 2022

The poster presentation will be made at the 12th European Meeting on Molecular Diagnostics (EMMD) taking place in Noordwijk, Netherlands from October 12 to 14, 2022.

Key Points: 
  • The poster presentation will be made at the 12th European Meeting on Molecular Diagnostics (EMMD) taking place in Noordwijk, Netherlands from October 12 to 14, 2022.
  • The poster will be available on Microbixs website (https://microbix.com) and from EMMD after its presentation.
  • However, MDx-based screening programs require rigorous workflow design and ongoing validation to ensure their accuracy.
  • Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Cervical Cancer Diagnostics Global Market Report 2022: Increasing Prevalence of STIs Escalates Risk & Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022

The "Cervical Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global cervical cancer diagnostics market size reached US$ 7.1 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 9.9 Billion by 2027, exhibiting a CAGR of 5.7% during 2021-2027.
  • Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Tuesday, October 4, 2022

We are very pleased to have received Fast Track designation from the FDA for CUE-101.

Key Points: 
  • We are very pleased to have received Fast Track designation from the FDA for CUE-101.
  • Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fulfill an unmet medical need.
  • A therapeutic candidate that receives Fast Track designation may be eligible for more frequent interactions with the FDA to discuss the therapeutic candidates development plan.
  • Therapeutic candidates with Fast Track designation may be eligible for accelerated approval and priority review if supported by clinical data.

SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy

Retrieved on: 
Monday, October 3, 2022

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ Activating Antigen Carrier (AAC) platform.

Key Points: 
  • SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ Activating Antigen Carrier (AAC) platform.
  • This paper demonstrates the potential of our technology to generate an effective red blood cell-derived cancer immunotherapy, said Howard Bernstein, M.D., Ph.D., Chief Scientific Officer at SQZ Biotechnologies.
  • We are excited about the preclinical findings of our AAC program, which has shown potential in both monotherapy settings and in combination with chemotherapy, said Scott Loughhead, Ph.D., VP of Translational Research at SQZ Biotechnologies.
  • SQZ AACs are generated by squeezing red blood cells (RBCs) with antigens and activating adjuvant.

The Fenway Institute Offers Recommendations for Improving Human Papillomavirus Vaccination Rates in US

Retrieved on: 
Sunday, October 2, 2022

BOSTON, October 02, 2022  /PRNewswire-PRWeb/ -- A policy brief published by The Fenway Institute at Fenway Health offers recommendations to health professionals and policy makers on how to improve Human Papillomavirus (HPV) vaccination rates in the U.S. HPV is the most common sexually transmitted infection (STI) in the world. Approximately 79 million Americans, most in their teens and early 20s, are infected with HPV despite the widespread availability of a safe and effective vaccine since 2006.

Key Points: 
  • But vaccination rates remain far below optimal rates of coverage, especially among male-identifying individuals.
  • There are other disparities in vaccination rates across populations of varying sexual and gender identities, as well as race and ethnicity.
  • The policy brief, titled "Improving Human Papillomavirus vaccination rates in the U.S.: Recommendations for health professionals and policy makers," addresses barriers to HPV vaccination, including the politicization of vaccines, sex and gender-based stigma, medical mistrust, misinformation, and insufficient provider recommendation.
  • "Improving Human Papillomavirus vaccination rates in the U.S.: Recommendations for health professionals and policy makers," is available for download as a PDF here .